-
Mashup Score: 3European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer - 7 month(s) ago
Following two Delphi rounds and expert panel discussions, the European Association of Nuclear Medicine Focus 5 meeting reached consensus for key statements regarding the role of advanced imaging techniques in prostate cancer. It also contoured the place of theranostics in relation to the classical approach of conservative hormonal therapies or chemotherapies.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 4
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice. This week on BackTable Urology, Dr. Suzette Sutherland (University of Washington) and Dr. Olivia Chang (UC Irvine) discuss reasons for uterine preservation and hysteropexy techniques for prolapse repair. This week on BackTable Urology, Dr. Suzette Sutherland and Dr. Rachel Rubin discuss the diagnosis
Source: cms.megaphone.fmCategories: Hem/Oncs, Latest HeadlinesTweet-
Professional highlight to interview Dr. Peter Scardino: gentleman, visionary, & juggernaut in our field! #UroSoMe #prostatecancer @BehfarEhdaie @UrologyMSK @UCSD_Urology @easthamja @AmerUrological @ericklein @MSKCancerCenter https://t.co/DtRgZYkU9T
-
-
Mashup Score: 0The role of SLAMF7-positive, CD8-positive T-cells in therapeutic resistance in kidney cancer - 8 month(s) ago
David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic techniques, such as single cell approaches, to uncover the causes of resistance to anti-PD1 therapy. Single cell RNA sequencing analysis from various clinical trial samples showed that slightly exhausted T-cells that expressed markers such as SLAMF7, were strongly linked with therapeutic resistance. This finding needs to be corroborated in other studies and requires functional testing, to uncover if this is a biomarker, predictive factor, or a component that can be modulated. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@BraunMDPhD of @YaleMed discusses using single-cell approaches to understand resistance to anti-PD1 therapy in kidney cancer. More research is needed to confirm its significance: ➡️https://t.co/Bg75pxiQKf⬅️ #ASCO23 #kcsm #UroOnc #UroSoMe
-
-
Mashup Score: 0MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer - 8 month(s) ago
Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shilpaonc (@ClevelndClinic) discusses the Phase III MAIN-CAV trial, aiming to improve outcomes for patients w/ metastatic UC via maintenance cabozantinib and avelumab: ➡️https://t.co/qMCOgJ49Dg⬅️ #ASCO23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM
-
-
Mashup Score: 0How can we best sequence novel treatments in urothelial cancer? - 8 month(s) ago
Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, comments on the changing field of urothelial cancer, including novel therapies such as enfortumab vedotin and erdafitinib, which have been assessed in the EV-103 trial (NCT03288545) and THOR (NCT03390504) trials, as well as sacituzumab govitecan. Treatment can depend on the FGFR status of patients, where erdafitinib has shown benefit in patients with FGFR alterations. Adverse events can additionally influence which drug a patient will receive. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@DanielPetrylak from @YaleMed discusses the evolving landscape of UC treatment, emphasizing the importance of patient-specific factors and FGFR status in guiding therapy decisions: ➡️https://t.co/5Rb8fCdTdT⬅️ #ASCO23 #BlcSM #UroOnc #UroSoMe #ImmunoOnc
-
-
Mashup Score: 1Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale - 8 month(s) ago
Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the rationale behind combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell renal cell carcinomas (RCC) in the Phase II KEYNOTE-B61 (NCT04704219) study. While most clinical trials have focused on clear cell RCC, a significant portion of patients have non-clear cell histologies, which historically have not responded well to existing systemic therapies. The combination of lenvatinib and pembrolizumab has shown impressive efficacy in clear cell RCC, prompting interest in exploring its potential benefits for non-clear cell histologies as well. The study aims to determine whether this combination therapy can be effective in improving outcomes for patients with non-clear cell RCC, offering a new treatment option for this subgroup of kidney cancer patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@ChungHanLee3 of @MSKCancerCenter explores the synergy of lenvatinib and pembrolizumab in treating non-clear cell RCC, offering new hope for kidney cancer patients. Learn more here: ➡️https://t.co/nNKpxxGe9V⬅️ #ASCO23 #ImmunoOnc #KCSM #UroOnc #UroSoMe
-
-
Mashup Score: 1
Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on updates from the CLIMATE trial (ACTRN12622000247774), which assessed the clinical utility of miR-371a-3p as a marker of residual disease in testicular cancer following orchiectomy. Having a post-operative biomarker will enable patients who test negative for minimal residual disease (MRD) to be spared treatment. Patients with seminoma and non-seminoma testicular cancer were recruited and the trial is currently ongoing. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@ciaraconduit from @PeterMacCC discusses promising updates from the CLIMATE trial, highlighting the potential of miR-371a-3p as a post-operative biomarker in testicular cancer: ➡️https://t.co/G8CbHIxyZk⬅️ #ANZUP23 #TSCSM #UroOnc #UroSoMe #CTSM
-
-
Mashup Score: 7Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study - 8 month(s) ago
In a large national cohort, high-risk prostate cancer (PC) was associated with substantially higher relative rates of depression and suicide, which persisted for ≥10 yr after PC diagnosis. PC survivors need long-term follow-up for timely detection and treatment of psychosocial distress.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet-
Current Issue: Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study https://t.co/mjS4adbw9a #prostatecancer #UroSoMe #Medtwitter https://t.co/gQFsu7mVGL
-
-
Mashup Score: 0Understanding variant histologies in urothelial carcinoma: IO and cabozantinib’s potential - 8 month(s) ago
Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, highlights the importance of understanding variant histologies in the context of treatment options for urothelial carcinoma, particularly immunotherapy and therapies like cabozantinib in neoadjuvant settings. Variant histologies in urothelial carcinoma often have limited alternatives compared to standard chemotherapy, and cystectomy is typically the first choice. However, emerging data from studies such as the Phase III KEYNOTE-045 (NCT02256436) and Phase II ARCADIA (NCT03824691) trials indicate that the treatment landscape for variant histologies could potentially change in the future. It is crucial to identify which subtypes of variants could benefit from pembrolizumab or the combination of durvalumab and cabozantinib. While the Arcadia trial is still ongoing and requires completion with 120 treated patients, the preliminary results are promising, indicating the need to further explore and understand
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@giannatempopatr emphasizes understanding variant histologies in UC treatment. Emerging data from trials like KEYNOTE-045 & ARCADIA could change the landscape for these variants: ➡️https://t.co/8Dm3BqClO2⬅️ #ASCO23 #BlcSM #CTSM #UroOnc #UroSoMe
-
-
Mashup Score: 0Pregnancy and Urology Residency: Towards Equity-centred Practice - 8 month(s) ago
For urology to be truly inclusive in the future, an equity-centred approach to pregnancy is required. Conditions for pregnant women and those caring for a newborn must be optimised to achieve this goal. The European Association of Urology could play a role in addressing the key issues and priorities and set an example for national urological associations.
Source: www.europeanurology.comCategories: Latest Headlines, UrologyTweet-
August 2023: Pregnancy and Urology Residency: Towards Equity-centred Practice https://t.co/1C5g011Bbx @LAUrology_NL @PignotG @Luca_Afferi @JLVasquez82 @carme_mir1 @BenjaminPradere #UroSoMe #Medtwitter
-
Articles in Press: European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer https://t.co/4C05mxe7XC #prostatecancer #medtwitter #UroSoMe https://t.co/uZ2vNVZth6